Compare AbCellera Biologics Inc (ABCL) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Exxon Mobil Corporation — how do they compare? AbCellera Biologics Inc trades at $7.2 (market cap $2.35B), while Exxon Mobil Corporation trades at $141.88 (market cap $587.30B). The key difference: Exxon Mobil Corporation is far larger — about 249.9× AbCellera Biologics Inc's market cap, and Exxon Mobil Corporation pays a 2.91% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | XOM | |
|---|---|---|
Market Cap | $2.35B | $587.30B |
Sector | Health | Energy |
52-Week High | $8.12 | $171.52 |
52-Week Low | $2.78 | $105.83 |
Enterprise Value | $1.99B | $626.52B |
Dividend Yield | — | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
ExxonMobil (XOM) trades at $136.44, down 0.42% on the day, with a bearish technical signal despite recent earnings beats. The company maintains strong operational cash flow of $52.0B in 2025 and a healthy balance sheet with 15.44% debt-to-capitalization. Recent news highlights Exxon's Permian Basin advantages and warnings about potential oil price spikes to $150-160 per barrel amid Middle East tensions.
XOM presents a mixed outlook with attractive valuation metrics (P/E 22.97, below energy sector average) and analyst consensus target of $172.79 (26% upside). However, declining revenue trends ($323.9B in 2025 vs. $398.7B in 2022) and bearish technical indicators suggest near-term headwinds. The stock offers income potential with recent $1.03 dividend but faces oil price volatility risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
